Cite
HARVARD Citation
Bayo, J. et al. (2018). Toxicity of docetaxel, carboplatin, and trastuzumab combination as adjuvant or neo‐adjuvant treatment for Her2 positive breast cancer patients and impact of colony‐stimulating factor prophylaxis. Breast journal. 24 (4), pp. 462-467. [Online].